Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult
to treat and carries a poor prognosis, with 50% of affected children progressing to end stage
renal disease (ESRD). The purpose of this study is to investigate oral galactose as a benign
treatment for FSGS in children. The investigators hypothesize that galactose, a simple milk
sugar thought to bind to the protein factor (FSPF) that causes FSGS thereby inactivating it
and stopping it from damaging the kidney, resulting in a reduction in glomerular permeability
to albumin and decrease in proteinuria in children with nephrotic syndrome secondary to FSGS.
Phase:
N/A
Details
Lead Sponsor:
Children's National Research Institute Children's Research Institute